EICHORCondition: Overweight or Obesity · Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study aims to compare the relative bioavailability, safety and tolerability of the first-generation and second-generation formulations of HRS9531 tablets, as well as to explore the safety, tolerability and pharmacokinetic characteristics of the second-generation formulation in terms of single-dose escalation.
This description comes directly from the study's public registry record.
Jingjing Wang · +86-0518-82342973 · jingjing.wang@hengrui.com
Tong Zhang · +86-0518-82342973 · tong.zhang.tz58@hengrui.com
Always discuss trial participation with your own doctor first.
| The Second Affiliated Hospital of Anhui Medical University | Hefei, Anhui, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07150962